（文章来源：证券日报） 证券日报网讯 12月12日，睿智医药在互动平台回答投资者提问时表示，截至11月30日公司的股东人数 为39844户。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：何俊熹 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：何俊熹 ...

在A股市场，上市公司董秘往往被视为连接公司与资本市场的"桥梁"，其任职者通常具备深厚的金融、 法律或行业专业背景。然而，睿智医药一则董秘聘任公告，却打破了市场对该岗位的固有认知——公司 拟聘任有多年广电主持经历的高莹莹担任新任董秘，此举迅速引发资本市场广泛关注。 投资者对这一人事任命褒贬不一。有观点认为高莹莹是外行，也有人认为其多年的媒体和主持人经验将 给公司品牌带来全新形象。 需要指出的是，睿智医药对董秘岗位的薪酬投入较为可观，该公司前任董秘2022~2024年三年间的平均 年薪约为154.08万元。如果延续这个薪酬水平，高莹莹未来的待遇也将较为丰厚。 从公开履历来看，高莹莹出生于1994年，本科学历，上海师范大学工商管理硕士在读。高莹莹自2016年 大学毕业就进入地方广播电视台，在随后的6年时间里先后任职于阳江广播电视台和中山广播电视台， 并担任策划、主持人、编导、编辑等职。其与双胞胎姐姐高晶晶共同主持过《晶莹睇透》《晶莹宝贝》 《文学悦听》《水上冲关》等栏目。期间，高莹莹还多次登上地方电视台春晚。 （文章来源：每日经济新闻） ...

Core Viewpoint - RuiZhi Pharmaceutical has appointed Gao Yingying as the new secretary of the board of directors following the resignation of Xu Jian due to work adjustments [1][5]. Group 1: Appointment Details - Gao Yingying's term as the board secretary will last until the end of the sixth board of directors [1]. - The appointment was approved by the board of directors after a nomination by Chairman Woo Sweelian [1]. Group 2: Background of Gao Yingying - Gao Yingying, born in 1994, has a bachelor's degree and is currently pursuing a master's degree in business administration at Shanghai Normal University [3]. - She has experience as a planner, host, and editor at various broadcasting stations from 2016 to 2022 [3][4]. - Prior to joining RuiZhi Pharmaceutical, she served as the promotion director at Zhongshan Anxin New Retail Co., Ltd. starting in November 2022 [4]. Group 3: Comparison with Previous Secretary - Xu Jian, the previous board secretary, was born in 1984 and held a master's degree in law from Sun Yat-sen University [4]. - Xu Jian had extensive experience in investment banking, having worked at Guohai Securities and Ping An Securities before joining RuiZhi Pharmaceutical in November 2021 [4][5]. Group 4: Company Performance - RuiZhi Pharmaceutical is a provider of integrated research and production services for biopharmaceuticals and chemical drugs [6]. - The company reported a total net loss exceeding 1.1 billion yuan over 2023 and 2024, with a revenue of 817 million yuan in the first three quarters of the current year, representing a year-on-year growth of 13.68% [6]. - The net profit attributable to shareholders for the same period was 7.09 million yuan, showing a significant increase of 111.5% year-on-year [6]. Group 5: Stock Performance - As of December 10, RuiZhi Pharmaceutical's stock price was 9.98 yuan per share, with a decline of 3.95% since the beginning of December [7]. - The company's latest market capitalization stands at 5 billion yuan [7].

每经记者｜黄宗彦 每经编辑｜吴永久 在A股市场，上市公司董秘往往被视为连接公司与资本市场的"桥梁"，其任职者通常具备深厚的金融、法律或行业专业背景。然而，睿智医药一则董秘聘任 公告，却打破了市场对该岗位的固有认知——公司拟聘任有多年广电主持经历的高莹莹担任新任董秘，此举迅速引发资本市场广泛关注。 投资者对这一人事任命褒贬不一。有观点认为高莹莹是外行，也有人认为其多年的媒体和主持人经验将给公司品牌带来全新形象。 需要指出的是，睿智医药对董秘岗位的薪酬投入较为可观，该公司前任董秘2022~2024年三年间的平均年薪约为154.08万元。如果延续这个薪酬水平，高莹 莹未来的待遇也将较为丰厚。 归根结底，外界所关注的核心问题是，抛开"美女主持人"的光环，这位无任何董秘和生物医药行业从业经历的新任董秘，将给公司带来哪些改变？ 睿智医药聘春晚主持人担任董秘，外界褒贬不一 2025年12月1日，睿智医药发布《关于变更董事会秘书的公告》，宣布公司董事会审议通过议案，同意聘任高莹莹为公司新任董事会秘书，任期自本次董事 会审议通过之日起至公司第六届董事会届满之日止。公告同时披露，前任董秘许剑因工作调整原因申请辞职，其原定任期至2 ...

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]

Core Insights - The chairman of Ruizhi Pharmaceutical, Hu Ruilian, emphasizes the importance of finding a unique path in a competitive market, particularly during a price war in the CXO industry [3][4] - Under Hu's leadership, the company achieved a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, marking a successful turnaround [3][4] - The company is focusing on a systematic strategic layout, including comprehensive service offerings, technological innovation, and global expansion [3][4] Financial Performance - In the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 534 million yuan, reflecting a 14.75% year-on-year growth [3] - The company achieved a net profit of 25.38 million yuan, successfully reversing previous losses [3] Strategic Transformation - Hu Ruilian initiated a transformation from a fragmented subcontracting model to a one-stop delivery service model, enhancing efficiency and customer satisfaction [4][5] - The new service model allows clients to specify their needs while the company manages the entire process, creating a competitive barrier in the market [5] Technological Innovation - The company has made significant advancements in technology, particularly with the launch of the micro-flow manufacturing system in collaboration with East China Normal University [6][7] - This system is expected to revolutionize drug manufacturing by significantly reducing production space and time, while also lowering costs and impurities [6][7] Market Expansion - Ruizhi Pharmaceutical is establishing a biopharmaceutical industrial park in Malaysia, which aims to serve as a bridge for Chinese pharmaceutical companies entering the ASEAN market [8] - The park is strategically positioned to access a large market of approximately 2 billion Muslims, leveraging Malaysia's authoritative halal certification [8] Global Strategy - The company has developed a clear global layout, combining a Shanghai R&D base, localized operations in Europe and the U.S., and the Malaysian industrial park to serve emerging markets [9] - This diversified approach allows Ruizhi Pharmaceutical to support both domestic biotech companies and international pharmaceutical firms [9]

胡瑞连 ◎记者 王墨璞嘉 初见睿智医药董事长胡瑞连，这位有着多次跨界创业成功经历的企业家，说话时语速平稳间透着果决。 谈及接手睿智医药的关键抉择，他回忆道："当时全行业都在打价格战，没人相信一家老牌CXO企业能 靠转型翻盘，但我始终觉得，越是红海市场，越要找到自己的专属航道。" "睿智医药有着多年医药研发及生产服务的经验积累，科学家团队很扎实，但分包服务模式已经跟不上 行业的发展了。"胡瑞连说。 胡瑞连迅速启动变革：一方面推行降本增效、开源节流，稳定管理层、重塑组织架构；另一方面大刀阔 斧重构商业模式，从"零散施工"的分包服务模式，转向"一站式交付"的整包服务模式。 "在整包服务模式下，客户只需明确需求，从靶点发现到工艺落地所有事我们一肩挑。同时，公司还能 凭借积累的专业经验，为药企研发提供针对性建议。"胡瑞连表示。 这一转型让睿智医药跳出了低价竞争的僵局。"国内能做分包服务的CXO企业有千余家，但能做全流程 整包服务的不超过五家。睿智医药通过战略重塑，构建了自身的竞争壁垒。"胡瑞连说。 2025年上半年，睿智医药实现营收5.34亿元，同比增长14.75%；实现归母净利润2538.21万元，成功扭 亏为盈。而 ...

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Core Viewpoint - Ruizhi Pharmaceutical (300149) announced the resignation of its board secretary, Xu Jian, due to work adjustments, effective immediately upon delivery of the resignation report [1] Group 1: Management Changes - Xu Jian will continue to serve as the Vice President of the Investment Development Department at Shanghai Ruizhi Pharmaceutical Research Group after resigning [1] - Gao Yingying has been appointed as the new board secretary, with her term lasting until the end of the sixth board session [1] Group 2: New Board Secretary Profile - Gao Yingying, born in 1994, is a Chinese national with no permanent residency abroad and is currently pursuing a Master's degree in Business Administration at Shanghai Normal University [1] - Her previous experience includes roles as a planner, host, director, and editor at various broadcasting stations from 2016 to 2022, and as a promotion director at Zhongshan Anxin New Retail Co., Ltd. from November 2022 to November 2025 [1]